Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...

Atezolizumab improved DFS and OS in ctDNA-positive MIBC patients, with a median DFS of 9.9 months vs 4.8 months for placebo. Serial ctDNA testing may offer a more accurate assessment of MRD and early ...

Physicians and patient advocacy groups are rallying behind a renewed legislative effort in Congress to amend what they claim ...

Drs Kathryn J. Ruddy and Shanda H. Blackmon discuss the importance of support groups and other ways to support cancer ...

Botox is widely known to iron out wrinkles, but it could also help ease phantom limb pain in Ukrainian war amputees, ...

For 36-year-old Luke Pomfret, a visit to the GP after months of sleepless nights was meant to be a simple solution. Instead, ...